Honestly, I can’t contribute any useful information on 3-71. I’ve not taken the time to parse out arcane details of the several technical papers on the molecule. My understandings of it are only cursory, derived from a quick read of the text associated with the article links, to whit: it, too, suppresses tau tangles, among other good effects.
I find most interesting the markedly small efficacious doses of this substance: 10 micrograms per kilogram per day. The stuff is apparently very active (although these were daily injections, not the more humanly convenient oral administration — not an obviating factor, as any of us with a treatable neurodegenerative disease would make a daily injection for effective treatment, as with diabetes).
For me (right now, at least, before human applications are revealed), as with 2-73, two controlling factors are known (at least in animals so far): a) low doses are effective, and equally important, b) no detectable side effects or adverse reactions, at experimental doses 50k times efficacy rates.
I challenge anyone to find any approved, “safe” neurologic drug that shows no side effects at 50k times normal dosages.
The drugs of Anavex are unique, unlike any others. They work, and they work in low doses. I’m eager to follow the development and applications of 3-71 and any others that might emerge.
Let me say, parenthetically, that all of this and more is being understood by neurologists and biochemists in a host of Big Pharma firms and academic institutions. I’m just a common biologist, with a modicum of neurological and biochemical expertise, and I can see the Big Picture. The phenomenal traits and potentials of Anavex’s drug candidates are not being neglected or dismissed behind closed doors. Common retail AVXL share purchasers are generally oblivious to the ever more clear future 2-73 and Anavex’s other drugs in development will produce. They tend to regard AVXL as a nice little, obscure equity and might double in a few months, yielding a 100% gain. Those with such perspectives are welcome to them. I wish them the best.
But, quietly, behind closed doors, a lot of pharmaceutical officers and research and development people are talking more openly and accurately about Anavex. The released clinical data are just too gigantic and substantiated to dismiss. Financial editors and writers are pretty much clueless, cautioning readers that most new drugs fail to get approved, or fail to perform. Risky business investing in drug start-ups.
Wish I had some funds to take a larger position. For those with appropriate levels of biochemical and neurological knowledge, it is clear that 2-73 and the others have no parallel and can revolutionize modern geriatric medicine. Gonna be fun watching how all of this develops. The Big Show will start when the curtain opens on the next Anavex act, when applicable human trials results are revealed. Naysayers can easily dismiss lab rat and mice data. Mice are not men. When real human efficacy trials appear, watch out.
AI
